nanotechnology, nanotechnology links, nanomaterials, nanomaterial database, nanotechnology news
.
Nanowerk article print Printer-friendly
Nanowerk article email E-mail this article
Nanowerk news digest Daily News Email Digest
Nanowerk News Feeds News Feeds
Nanowerk on Facebook Join us on Facebook
Nanowerk on Twitter Follow us on Twitter
Bookmark Nanowerk Directory
 
Posted: Feb 14th, 2012
Posted: Feb 13th, 2012
Posted: Feb 13th, 2012
Posted: Feb 13th, 2012
Posted: Feb 13th, 2012
Posted: Feb 13th, 2012
Posted: Feb 13th, 2012
Posted: Feb 13th, 2012
Posted: Feb 9th, 2012
Posted: Feb 9th, 2012
Posted: Feb 9th, 2012
Posted: Feb 8th, 2012
Posted: Feb 8th, 2012
Posted: Feb 8th, 2012
Posted: Feb 7th, 2012
Posted: Feb 7th, 2012
Posted: Feb 7th, 2012
Posted: Feb 7th, 2012
Posted: Feb 7th, 2012
Posted: Feb 6th, 2012
 
Posted: March 19, 2010
Nanosphere Verigene SP Respiratory Virus Panel Categorized as Moderate Complexity by FDA
(Nanowerk News) Nanosphere, Inc., a leader in the development and commercialization of advanced molecular diagnostics systems, received notification from the U.S. Food and Drug Administration (FDA) that its respiratory virus panel (RVNATSP) performed on the Verigene SP System has been categorized as "Moderate Complexity" under the Clinical Laboratory Improvement Amendments of 1988 (CLIA).
The "Moderate Complexity" designation allows the test to be run in more settings by a broader group of operators.
The RVNATSP assay on the Verigene SP is the first Nanosphere test categorized as "Moderate Complexity" by the FDA. Nanosphere's previously cleared FDA products have been categorized as "High Complexity" and run on the original Verigene system. The company plans to file all of its previously cleared and future assays on the Verigene SP, which automates sample preparation, and should enable more tests to be categorized as "Moderate Complexity."
"This CLIA categorization is another validation of the value of our technology and its ease of use," said William Moffitt, Nanosphere's President and Chief Executive Officer. "It broadens our market for the Verigene SP and provides customers with the first 'Moderate Complexity' molecular flu test," Mr. Moffitt explained.
The Verigene(R) System is a benchtop molecular diagnostics workstation that utilizes patented gold nanoparticle technology to detect nucleic acid and protein targets of interest for a variety of applications. The Verigene(R) SP System adds automated sample preparation to the original Verigene(R) System, allowing for sample-to-result capabilities.
About Nanosphere, Inc.
Nanosphere develops, manufactures and markets an advanced molecular diagnostics platform, the Verigene(R) System, for direct genomic and ultra-sensitive protein detection. This easy to use and cost effective platform enables simple, low cost and highly sensitive genomic and protein testing on a single platform. Nanosphere is based in Northbrook, IL.
Source: Nanosphere (press release)

Subscribe to a free copy of our daily

Nanowerk Nanotechnology News Email Digest

with a compilation of all of the day's news.

 
 
 
 
Privacy statement | Terms of use | Contact us | Home | Sitemap | Advertise with us
The contents of this site are copyright ©2012, Nanowerk. All Rights Reserved